Tariffs Lift Camlin Fine but the Real Story Lies in Blends

Tariffs are lifting Camlin Fine Sciences currently, but the company is quietly trying to become a very different business. The market appears to be pricing both stories at the same time. The reduction in US import duties on Indian vanillin from 50% to 25% has improved near-term realisations from approximately $12.50 per kg to roughly $14.50 in October-December. That is a significant improvement, but contingent on trade policy that has already moved twice in twelve months.

To understand the company properly, it helps to see what its products are and where they fit in. Camlin operates inside a segment of global food supply chains that attracts little investor attention despite being structurally indispensable in the food business.

Oils, fats, and nutrients degrade when exposed to oxygen, shortening shelf life and degrading flavour, colour, and nutritional value across long storage and shipping cycles. Food manufacturers, feed producers, and cosmetics companies depend on antioxidants and stabilising additives to slow that process. The chemistry is specialised and the industrial need is universal and growing.

Camlin’s financial structure reflects two businesses operating inside one chain.

Camlin effectively runs two businesses, a commodity antioxidant segment called Straights and a higher-margin formulation business known as Blends. The phenol platform runs from catechol and hydroquinone through TBHQ and BHA to vanillin, ensuring plant utilisation while supplying the company’s higher value ingredients portfolio. In practice it means the company carries the cost structure of a chemical manufacturer while trying to capture the margins of a specialty ingredients supplier. The December quarter made that visible with unusual clarity. Revenue reached ₹4.57 billion. Adjusted EBITDA margin fell to 6.7% from 14.4% a year earlier. Pricing pressure in the Straights antioxidant business absorbed the gains from Blends growth entirely.

Camlin Fine’s cost base still reflects the economics of commodity chemicals. In this business, the real money is rarely in the intermediate molecule. International Flavors and Fragrances built durable margins by concentrating on formulation and customer integration rather than defending upstream intermediate volumes. Camlin still manufactures large quantities of chemical inputs while selling additives further along the chain. This results in the company neither getting volume benefits of a pure commodity producer nor the margin premium of a pure formulation house. The Vinpai acquisition, an 83.82% stake in a French natural functional ingredients manufacturer with 3,500 formulations serving 36 countries, signals that the management understands where it needs to go.

The strongest argument in Camlin’s favour begins with vanillin pricing. Few producers outside China supply the global market, which makes trade barriers unusually powerful. Trade barriers continue to limit Chinese vanillin supply in major markets. Europe imposes anti-dumping duties of approximately 131% on Chinese vanillin while the US has maintained elevated tariff protection. Camlin plans to ramp vanillin production to roughly 4,000 tonnes in 2026–27 from about 2,300 tonnes in 2025–26, which could materially lift earnings if protection holds. Management expects EBITDA margins of 12–14% this year, supported by higher vanillin realisations and continued growth in blends.

The complication is that Camlin's own actions during the December quarter reveal the limits of that dependence. The management deliberately withheld approximately 200 tonnes of vanillin sales, holding channel inventory near 550 tonnes to capture better pricing after the anticipated tariff reduction. That is rational short-term treasury management. It is also confirmation that the business currently optimises around trade policy timing rather than structural demand signals. A true specialty ingredients business earns its margins from formulations and customer relationships. It does not wait for tariff changes to book revenue.

That contradiction is precisely what investors pricing both the tariff recovery and the specialty re-rating simultaneously are choosing to ignore. Camlin Fine is investing in blends, natural ingredients, and customer integration because formulated ingredients command margins that commodity antioxidants cannot match. The market will eventually have to choose between the tariff story and the specialty story.

(This column reflects the author’s personal views and is based on publicly available information. It is intended for general commentary and analytical purposes only and should not be construed as investment advice.)